Literature DB >> 6806221

Computed tomography in definitive radiotherapy of prostatic carcinoma, part 2: definition of target volume.

M V Pilepich, S C Prasad, C A Perez.   

Abstract

Pretreatment computed tomography (CT) scanning of the pelvis was performed in 100 consecutive patients with carcinoma of the prostate treated with external irradiation (82 patients) or interstitial I125 (18 patients). Treatment plan modifications prompted by CT scan findings were most frequent in patients with (clinical) involvement of the seminal vesicles in whom the conventional treatment planning often resulted in an underestimate of tumor volume. Seventeen of 32 (53%) such patients required an enlargement of treatment fields to adequately encompass the target volume. Using skeletal landmarks as reference, the dimensions of the prostate, seminal vesicles and the detectable tumor and their topographic relationships were systematically tabulated. These measurements provide a basis for the definition of the target volume in patients with carcinoma of the prostate in whom CT scans might not be available.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6806221     DOI: 10.1016/0360-3016(82)90519-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

1.  [Planned 3-dimensional low-volume conformal irradiation of a local prostatic carcinoma].

Authors:  S Wachter; N Gerstner; K Dieckmann; M Stampfer; R Hawliczek; R Pötter
Journal:  Strahlenther Onkol       Date:  1997-05       Impact factor: 3.621

Review 2.  The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients.

Authors:  Ashesh B Jani; Stanley L Liauw; Michael J Blend
Journal:  Clin Med Res       Date:  2007-06

3.  A simple algorithm to assess patient suitability for Calypso-seed implantation for four-dimensional prostate localization.

Authors:  Randall J Kimple; Eric M Wallen; Raj Pruthi; Lawrence B Marks
Journal:  J Appl Clin Med Phys       Date:  2009-12-03       Impact factor: 2.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.